PedAM
Pediatric Disease Annotations & Medicines
| sciatic neuropathy | ||||
| Disease ID | 1365 |
|---|---|
| Disease | sciatic neuropathy |
| Definition | Disease or damage involving the SCIATIC NERVE, which divides into the PERONEAL NERVE and TIBIAL NERVE (see also PERONEAL NEUROPATHIES and TIBIAL NEUROPATHY). Clinical manifestations may include SCIATICA or pain localized to the hip, PARESIS or PARALYSIS of posterior thigh muscles and muscles innervated by the peroneal and tibial nerves, and sensory loss involving the lateral and posterior thigh, posterior and lateral leg, and sole of the foot. The sciatic nerve may be affected by trauma; ISCHEMIA; COLLAGEN DISEASES; and other conditions. (From Adams et al., Principles of Neurology, 6th ed, p1363) |
| Synonym | nerve disease, sciatic nerve diseases, sciatic neuropathies, sciatic neuropathy, sciatic sciatic nerve dis sciatic nerve disease sciatic nerve diseases sciatic nerve--diseases sciatic neuropathies sciatic neuropathy (disorder) sciatic neuropathy [disease/finding] |
| DOID | |
| UMLS | C0149940 |
| MeSH | |
| SNOMED-CT | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:2) |
| Curated Gene | Entrez_id | Symbol | Resource(Total Genes:4) |
| Inferring Gene | (Waiting for update.) |
| Text Mined Gene | Entrez_id | Symbol | Score | Resource(Total Genes:14) 7132 | TNFRSF1A | DISEASES 9098 | USP6 | DISEASES 9172 | MYOM2 | DISEASES 4851 | NOTCH1 | DISEASES 7082 | TJP1 | DISEASES 8625 | RFXANK | DISEASES 5155 | PDGFB | DISEASES 4803 | NGF | DISEASES 7133 | TNFRSF1B | DISEASES 3604 | TNFRSF9 | DISEASES 6164 | RPL34 | DISEASES 7442 | TRPV1 | DISEASES 6336 | SCN10A | DISEASES 102723508 | KANTR | DISEASES |
| Locus | (Waiting for update.) |
| Disease ID | 1365 |
|---|---|
| Disease | sciatic neuropathy |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:4) |
| Disease ID | 1365 |
|---|---|
| Disease | sciatic neuropathy |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | (Waiting for update.) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:5) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0149940 | cisplatin | D002945 | 15663-27-1 | sciatic neuropathy | MESH:D020426 | marker/mechanism | 8397481 | ||
| C0149940 | paclitaxel | D017239 | - | sciatic neuropathy | MESH:D020426 | marker/mechanism | 11022860 | ||
| C0149940 | phenindione | D010630 | 1983/12/5 | sciatic neuropathy | MESH:D020426 | marker/mechanism | 4291162 | ||
| C0149940 | pregabalin | D000069583 | - | sciatic neuropathy | MESH:D020426 | therapeutic | 26102012 | ||
| C0149940 | vincristine | D014750 | - | sciatic neuropathy | MESH:D020426 | marker/mechanism | 26102012 | ||
FDA approved drug and dosage information(Total Drugs:3) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D020426 | lyrica | pregabalin | 25MG | CAPSULE;ORAL | Prescription | None | Yes | No |
| MESH:D020426 | lyrica | pregabalin | 25MG | CAPSULE; ORAL | Prescription | None | No | No |
| MESH:D020426 | lyrica | pregabalin | 25MG | CAPSULE; ORAL | Prescription | None | No | No |
FDA labeling changes(Total Drugs:3) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D020426 | 12/22/2016 | lyrica | pregabalin | Fibromyalgia | Safety and efficacy in pediatric patients have not been established. A 15-week, placebo-controlled trial was conducted with 107 pediatric patients with fibromyalgia, ages 12 through 17 years . The primary efficacy endpoint of change from baseline to Week 15 in mean pain intensity showed numerically greater improvement for the pregabalin-treated patients compared to placebo-treated patients, but did not reach statistical significance. The most frequently observed adverse reactions in the clinical trial included dizziness, nausea, headache, weight increased, and fatigue. The overall safety profile in adolescents was similar to that observed in adults with fibromyalgia. Postmarketing study. | Labeling | - | P | - | - | PF Prism CV | - | FALSE |
| MESH:D020426 | 12/22/2016 | lyrica | pregabalin | Fibromyalgia | Safety and efficacy in pediatric patients have not been established. A 15-week, placebo-controlled trial was conducted with 107 pediatric patients with fibromyalgia, ages 12 through 17 years . The primary efficacy endpoint of change from baseline to Week 15 in mean pain intensity showed numerically greater improvement for the pregabalin-treated patients compared to placebo-treated patients, but did not reach statistical significance. The most frequently observed adverse reactions in the clinical trial included dizziness, nausea, headache, weight increased, and fatigue. The overall safety profile in adolescents was similar to that observed in adults with fibromyalgia. Postmarketing study. | Labeling | - | P | - | - | PF Prism CV | - | FALSE |
| MESH:D020426 | 12/22/2016 | lyrica | pregabalin | Fibromyalgia | Safety and efficacy in pediatric patients have not been established. A 15-week, placebo-controlled trial was conducted with 107 pediatric patients with fibromyalgia, ages 12 through 17 years . The primary efficacy endpoint of change from baseline to Week 15 in mean pain intensity showed numerically greater improvement for the pregabalin-treated patients compared to placebo-treated patients, but did not reach statistical significance. The most frequently observed adverse reactions in the clinical trial included dizziness, nausea, headache, weight increased, and fatigue. The overall safety profile in adolescents was similar to that observed in adults with fibromyalgia. Postmarketing study. | Labeling | - | P | - | - | PF Prism CV | - | FALSE |